does the chemo backbone matter? wells messersmith, md, facp professor director, gastrointestinal...
TRANSCRIPT
![Page 1: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/1.jpg)
Does the Chemo Backbone Matter?
Wells Messersmith, MD, FACPProfessor
Director, Gastrointestinal Medical Oncology ProgramCo-Head, Division of Medical Oncology
Program co-Leader, Developmental TherapeuticsMarch 2014
![Page 2: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/2.jpg)
Conflict of Interest:
1. No employment, speaker’s bureaus, stock ownership, royalties, patents, etc
2. Data Safety Monitoring Board for OncoMed
3. PI or Local PI of clinical trials by Genentech/Roche, GSK, Pfizer, Millenium, Bayer, Onconova, and NIH/CTEP.
![Page 3: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/3.jpg)
Outline/Objectives:
1. Cross-Trial Comparisons
2. Randomized Data
3. Clinical Databases
4. Conclusions
Chemotherapy Backbones & Biologics
![Page 4: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/4.jpg)
Efficacy Comparison (Historical Controls)
Cetux-Irino(historical)
Cetux-Irino + Bev P value
Resp Rate 23% 37% 0.03
TTP 4 m 7.9 m <0.01
Cetux alone(historical)
Cetux + BevP value
Resp Rate 11% 20% 0.05
TTP 1.5 m 5.6 m <0.01
Saltz, “BOND2”, ASCO 2005
![Page 5: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/5.jpg)
CAIRO2: did not confirm
Tol, NEJM 2009
- Worse outcomes (PFS and strong trend in OS) when “double biologics” are used.
- Unexpected, and still mostly unexplained, result which shows why randomized trials are needed.
![Page 6: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/6.jpg)
The dangers of cross-trial comparisons
1. Lining up trials side by side, and drawing conclusions based on patterns that are seen, represents good scholarship and can generate important hypotheses.
2. However, there are known and unknown factors with various studies: different countries, standards, tolerance, etc
Whenever possible, randomized studies are needed to actually change practice
![Page 7: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/7.jpg)
Outline/Objectives:
1. Cross-Trial Comparisons
2. Randomized Data
3. Clinical Databases
4. Conclusions
Chemotherapy Backbones & Biologics
![Page 8: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/8.jpg)
CELIM study: Cetx + chemo
Folprecht, ASCO 2012
![Page 9: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/9.jpg)
CELIM study: No difference between chemo backbones
Folprecht, ASCO 2012
FOLFOX/Cetx
FOLFIRI/Cetx
This was a randomized phase II study with RR as primary endpoint
However, no difference is response or survival based on chemo backbone.
![Page 10: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/10.jpg)
CECOG: Cetuximab + FOLFOX v FOLFIRI
Ocverk, World J GI 2010
![Page 11: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/11.jpg)
Ocverk, World J GI 2010
CECOG: No difference between chemo backbones
This was a randomized phase II study with PFS at 9m as primary endpoint.
Again, no difference in response or survival based on chemo backbone.
![Page 12: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/12.jpg)
TRIBE Trial: Addition of Oxaliplatin
Falcone, ASCO 2013
![Page 13: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/13.jpg)
Adding Oxaliplatin to Backbone
Falcone, ASCO 2013
Primary endpoint of PFS was met!
![Page 14: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/14.jpg)
TRIBE Trial: Overall Survival
Falcone, ASCO 2013
![Page 15: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/15.jpg)
Randomized Trials for chemo “backbones:
1. CELIM trial- Cetuximab + FOLFOX vs. FOLFIRI
2. CECOG trial- Cetuximab + FOLFOX vs. FOLFIRI
3. TRIBE- Bevacizumab + FOLFIRI vs FOLFOXIRI
Zero for three in terms of showing any specific detriment or advantage to the
chemo backbone!
![Page 16: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/16.jpg)
Outline/Objectives:
1. Cross-Trial Comparisons
2. Randomized Data
3. Clinical Databases
4. Conclusions
Chemotherapy Backbones & Biologics
![Page 17: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/17.jpg)
ARIES: Observational Study
Bendell, Oncologist 2012
![Page 18: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/18.jpg)
ARIES
Bendell, Oncologist 2012
No difference in PFS or
OS for >1200 “real
world” patients.
![Page 19: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/19.jpg)
ARIES: Efficacy
Bendell, Oncologist 2012
No significant (or even insignificant) differences with regard to chemo backbone when combined with bev.
![Page 20: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/20.jpg)
ARIES: adverse events
Bendell, Oncologist 2012
Small differences in protocol-specified adverse events with regard to chemo backbone when combined with bev; but overall incidence very low.
![Page 21: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/21.jpg)
Outline/Objectives:
1. Cross-Trial Comparisons
2. Randomized Data
3. Clinical Databases
4. Conclusions
Chemotherapy Backbones & Biologics
![Page 22: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/22.jpg)
Conclusions (1)
- Head-to-head randomized studies show no difference in terms of which chemo backbone is paired with biologics.- Many of these are phase II
- For bevacizumab, large clinical databases show no difference.
- Cross-trial comparisons are complicated and can lead us down the wrong path (think of all of the patients treated with double biologics from 2005-2007).
- Until we know biomarkers (with positive predictive value) for biologics, difficult to assess and model whether specific chemotherapies modify them.
![Page 23: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/23.jpg)
Conclusions (2)
- Unclear whether investment of increasingly precious resources (patients, $$$, time) is worthwhile. - Study design: “rum and coke” v. “rum and pepsi”- Overlapping toxicities and PK issues usually more
relevant.
- The number of possible agents and combinations allow plenty of flexibility for oncologists uncomfortable with specific combinations.
- Would be better to dedicate resources to prevention, novel agents, and patient subsets/personalized medicine.
![Page 24: Does the Chemo Backbone Matter? Wells Messersmith, MD, FACP Professor Director, Gastrointestinal Medical Oncology Program Co-Head, Division of Medical](https://reader030.vdocuments.us/reader030/viewer/2022020117/56649cb85503460f9497ebc1/html5/thumbnails/24.jpg)
Ongoing “Chemo Backbone” Trials
- MAVERICC (NCT01374425), n=360, randomized pII- FOLFIRI/bev vs FOLFOX/bev
- PLANET (NCT00885885), n=80, pII- FOLFIRI/Pmab vs FOLFOX/Pmab
- VISNU-1 (NCT01640405), n=350, pIII- FOLFOXIRI/bev vs FOLFOX/bev
- CELIM2 (NCT01802645), n=256, pII- FOLFOXIRI vs FOLFIRI + Bev (KRAS MT) or
Cetuximab (KRAS WT)